


CLAIMS

1. A combination product comprising:

- 5 (i) a compound selected from NTZ and an analogue thereof ; and
 (ii) an anti-NASH, anti-fibrotic or anti-cholestatic agent,
 with the proviso that the anti-NASH, anti-fibrotic or anti-cholestatic agent is not a PPAR agonist.

- 10 2. The combination product according to claim 1, wherein component (i) is a compound of formula (I):




or a pharmaceutical acceptable salt thereof, in which :


- 15 R₁ represents a hydrogen atom (H), a deuterium atom (D), a halogen atom, a (C₆-C₁₄)aryl group, a heterocyclic group, a (C₃-C₁₄)cycloalkyl group, a (C₁-C₆)alkyl group, a sulfonyl group, a sulfoxide group, a (C₁-C₆)alkylcarbonyl group, a (C₁-C₆)alkyloxy, a carboxylic group, a carboxylate group, a nitro group (NO₂), an amino group (NH₂), a (C₁-C₆)alkylamino group, an amido group, a (C₁-C₆)alkylamido group, a (C₁-C₆)dialkylamido group.
- 20 R₂ represents a hydrogen atom, a deuterium atom, a NO₂ group, a (C₆-C₁₄)aryl group, a heterocyclic group, a halogen atom, a (C₁-C₆)alkyl group, a (C₃-C₁₄)cycloalkyl group, a (C₂-C₆)alkynyl group, a (C₁-C₆)alkyloxy group, a (C₁-C₆)alkylthio group, a (C₁-C₆)alkylcarbonyl group, a (C₁-C₆)alkylcarbonylamino group, a (C₆-C₁₄)arylcarbonylamino group, a carboxylic or carboxylate group, an amido group, a (C₁-C₆)alkylamido group, a (C₁-C₆)dialkylamido group, a NH₂ group, a (C₁-C₆)alkylamino group,
- 25 or R₁ and R₂, together with the carbon atoms to which they are attached, form a substituted or unsubstituted 5- to 8- membered cycloalkyl, heterocyclic or aryl group,
 R₃, R₄, R₅, R₆, and R₇, identical or different, represent a hydrogen atom, a deuterium atom, a halogen atom, a hydroxyl group, a (C₁-C₆)alkylcarbonyl group, an (C₁-C₆)alkyl group, an

(C1-C6)alkyloxy group, an (C1-C6)alkylthio group, an (C1-C6)alkylcarbonyloxy group, an (C6-C14)aryloxy group, a (C6-C14)aryl group, a heterocyclic group, a (C3-C14)cycloalkyl group, a NO₂ group, a sulfonylaminoalkyle group, an NH₂ group, an amino(C1-C6)alkyl group, an (C1-C6)alkylcarbonylamino group, a carboxylic group, a carboxylate group, or a
 5 R₉ group;

R₉ represents a O-R₈ group or an amino-acid selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or a moiety of formula (A):




wherein R' represents an (C1-C6)alkyl group, an (C2-C6)alkenyl group, an (C2-C6)alkynyl group, a (C3-C14)cycloalkyl group, (C3-C14)cycloalkylalkyl group, a (C3-C14)cycloalkyl(C2-C6)alkenyl group, a (C3-C14)cycloalkenyl group, a (C3-C14)cycloalkenyl(C1-C6)alkyl group, a (C3-C14)cycloalkenyl(C2-C6)alkenyl group, a (C3-C14)cycloalkenyl(C2-C6)alkynyl group;
 15 R'' and R''', independently, represent hydrogen atom, an (C1-C6)alkyl group, or a nitrogen protecting group.



R₈ represents a hydrogen atom, a deuterium atom, a glucuronidyl group, or a group wherein, R_{8a}, R_{8b} and R_{8c}, identical or different, represent a hydrogen atom or a deuterium atom.


20

3. The combination production of claim 1 or 2, wherein component (i) is a compound of formula (II):



or a pharmaceutically acceptable salt thereof, in which R₉ represents a hydrogen atom, a deuterium atom, a O-R₈ group, or an aminoacid selected from the group consisting of
 25

alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or a moiety of formula (A):



- 5 wherein R' represents an (C1-C6)alkyl group, an (C2-C6)alkenyl group, an (C2-C6)alkynyl group, a (C3-C14)cycloalkyl group, (C3-C14)cycloalkyl(C1-C6)alkyl group, a (C3-C14)cycloalkyl(C1-C6)alkenyl group, a (C3-C14)cycloalkenyl group, a (C3-C14)cycloalkenyl(C1-C6)alkyl group, a (C3-C14)cycloalkenyl(C2-C6)alkenyl group, a (C3-C14)cycloalkenyl(C2-C6)alkynyl group; R'' and R''', independently, represent a hydrogen atom, an (C1-C6)alkyl group, or a nitrogen protecting group
- 10 or a pharmaceutically acceptable salt thereof.

4. The combination product according to any one of claims 1 to 3, wherein component (i) is selected from nitazoxanide, tizoxanide, [(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl (d3)ethanoate, 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl (d2) ethanoate, 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl (d1) ethanoate, 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl 2-amino-3,3-dimethylbutanoate, 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl 2-amino-3-methylpentanoate, 2-(5-chlorothiazol-2-ylcarbamoyl)phenyl 2-amino-3,3-dimethylbutanoate, 2-(5-chlorothiazol-2-ylcarbamoyl)phenyl 2-amino-3-methylpentanoate or a pharmaceutically
- 15 acceptable salt thereof.

5. The combination production according to any one of claims 1 to 4, wherein component (i) is nitazoxanide or a pharmaceutically acceptable salt thereof.

- 25 6. The combination product according to any one of claims 1 to 5, wherein component (ii) is a ROCK2 inhibitor (in particular KD-025), an ACC inhibitor (in particular GS-0976), a dual inhibitor of NADPH oxidase isoforms NOX4 and NOX1 (in particular GKT-831), an ASK1 inhibitor (in particular selonsertib), a Fatty Acid Bile Acid Conjugate (in particular Aramchol), an FXR agonist (in particular Tropicorex), and a CCR antagonist (in particular CVC).

30

7. The combination product according to any one of claims 1 to 6, wherein component (ii) is obeticholic acid, aramchol, SHP-625, emricasan, IMM-124-E, GS-9674, NGM-282, A-4250, cenicriviroc, GR-MD-02, GS-4997, Tropicorex (LJN-452), F-351, solithromycin, remogliflozin,

BTT-1023, KD-025, PEG-FGF21, tipelukast, VK-2809, MGL-3196, GS-0976, RG-125, volixibat, ursodeoxycholic acid, semaglutide, GSK2330672, or a pharmaceutical salt thereof.

8. The combination product according to any one of claims 1 to 7, comprising:

- 5 (i) a compound selected from nitazoxanide, tizoxanide, [(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl (d3)ethanoate, 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl (d2) ethanoate; or 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl (d1) ethanoate, 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl 2-amino-3,3-dimethylbutanoate, 2-(5-nitrothiazol-2-ylcarbamoyl)phenyl 2-amino-3-methylpentanoate, 2-(5-chlorothiazol-2-ylcarbamoyl)phenyl 2-amino-3,3-dimethylbutanoate, 2-(5-chlorothiazol-2-ylcarbamoyl)phenyl 2-amino-3-methylpentanoate; or
10 from a pharmaceutical salt thereof; and

(ii), GS-0976, GS-4997 (Selonsertib), GKT-831 (formerly GKT137831), KD-025, Cenicriviroc (CVC), Aramchol, and Tropifexor (LJN-452) or a pharmaceutically acceptable salt thereof.

15

9. The combination product according to any one of claims 1 to 8, wherein the combination product is a composition comprising components (i) and (ii) and a pharmaceutically acceptable carrier.

- 20 10. The combination product according to any one of claims 1 to 9, wherein the combination product is a kit of parts comprising components (i) and (ii), for sequential, separate or simultaneous use.

- 25 11. The combination product according to any one of claims 1 to 10, wherein components (i) and (ii) are formulated in an injectable suspension, a gel, an oil, a pill, a tablet, a suppository, a powder, a capsule, an aerosol, an ointment, a cream, a patch, or means of galenic forms for a prolonged and/or slow release.

- 30 12. The combination product according to any one of claims 1 to 11, for use as a medicament.

13. The combination product according to any one of claims 1 to 11, for use in a method for treating an inflammatory, metabolic, fibrotic and cholestatic disease.

- 35 14. The combination product for use according to claim 13, wherein the fibrotic disorder is selected in the group consisting of liver, kidney, skin, epidermis, endodermis, muscle,

tendon, cartilage, heart, pancreas, lung, uterus, nervous system, testis, penis, ovary, adrenal gland, artery, vein, colon, intestine (e.g. small intestine), biliary tract, soft tissue (e.g. mediastinum or retroperitoneum), bone marrow, joint and stomach fibrosis, in particular liver, gut, lung, heart, kidney, muscle, skin, soft tissue, bone marrow, intestinal, eye and joint
 5 fibrosis.

15. The combination product for use according to claim 13, wherein the disease is selected in the group consisting of metabolic liver diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced liver diseases, alcohol-induced liver
 10 diseases, infectious agent induced liver diseases, inflammatory liver diseases, immune system dysfunction-mediated liver diseases, dyslipidemia, cardiovascular diseases, restenosis, syndrome X, metabolic syndrome, diabetes, obesity, hypertension, chronic cholangiopathies such as Primary Sclerosing Cholangitis (PSC), Primary Biliary Cholangitis (PBC), biliary atresia, familial intrahepatic cholestasis type 3 (PFIC3), inflammatory bowel
 15 diseases, Crohn's disease, ulcerative colitis, keloid, old myocardial infarction, scleroderma/systemic sclerosis, inflammatory diseases, neurodegenerative diseases, cancers, liver cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, meningioma associated with neurofibromatosis, pancreatic neuroendocrine tumors, pancreatic exocrine tumors, leukemia, myeloproliferative/myelodysplastic diseases,
 20 mastocytosis, dermatofibrosarcoma, solid tumors including breast, lung, thyroid or colorectal cancer, a prostate cancer, liver fibrosis or cirrhosis of any origin, metabolic disease-induced liver fibrosis or cirrhosis, NAFLD-induced fibrosis or cirrhosis, NASH-induced fibrosis or cirrhosis, alcohol-induced liver fibrosis or cirrhosis, drug-induced liver fibrosis or cirrhosis, infectious agent-induced liver fibrosis or cirrhosis, parasite infection-induced liver fibrosis or
 25 cirrhosis, bacterial infection-induced liver fibrosis or cirrhosis, viral infection-induced fibrosis or cirrhosis, HBV-infection induced liver fibrosis or cirrhosis, HCV-infection induced liver fibrosis or cirrhosis, HIV-infection induced liver fibrosis or cirrhosis, dual HCV and HIV-infection induced liver fibrosis or cirrhosis, radiation- or chemotherapy-induced fibrosis or cirrhosis, biliary tract fibrosis, liver fibrosis or cirrhosis due to any chronic cholestatic disease, gut fibrosis of any etiology, Crohn's disease-induced fibrosis, ulcerative colitis-induced
 30 fibrosis, intestine (e.g. small intestine) fibrosis, colon fibrosis, stomach fibrosis, skin fibrosis, epidermis fibrosis, endodermis fibrosis, skin fibrosis due to scleroderma/systemic sclerosis, lung fibrosis, lung fibrosis consecutive to chronic inflammatory airway diseases, such as COPD, asthma, emphysema, smoker's lung, tuberculosis, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), heart fibrosis, kidney fibrosis, nephrogenic systemic fibrosis, muscle
 35 fibrosis, soft tissue (e.g. mediastinum or retroperitoneum) fibrosis, bone marrow fibrosis, joint

fibrosis, tendon fibrosis, cartilage fibrosis, pancreas fibrosis, uterus fibrosis, nervous system fibrosis, testis fibrosis, ovary fibrosis, adrenal gland fibrosis, artery fibrosis, vein fibrosis, eye fibrosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis (a complication of coal workers' pneumoconiosis), proliferative
5 fibrosis, neoplastic fibrosis, peri-implantational fibrosis and asbestosis, arthrofibrosis, adhesive capsulitis.

16. The combination product for use according to claim 13, wherein the disease is selected in the group consisting of, the disease is selected in the group consisting of metabolic liver
10 diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced liver diseases, alcohol-induced liver diseases, infectious agent induced liver diseases, inflammatory liver diseases, immune system dysfunction-mediated liver diseases, dyslipidemia, cardiovascular diseases, restenosis, syndrome X, metabolic syndrome, diabetes, obesity, hypertension, chronic cholangiopathies such as Primary Sclerosing
15 Cholangitis (PSC), Primary Biliary Cholangitis (PBC), biliary atresia, familial intrahepatic cholestasis type 3 (PFIC3), inflammatory bowel diseases, Crohn's disease, ulcerative colitis, liver cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, colorectal cancer, metabolic disease-induced liver fibrosis or cirrhosis, NAFLD-induced fibrosis or cirrhosis, NASH-induced fibrosis or cirrhosis, alcohol-induced liver fibrosis or cirrhosis, drug-
20 induced liver fibrosis or cirrhosis, infectious agent-induced liver fibrosis or cirrhosis, parasite infection-induced liver fibrosis or cirrhosis, bacterial infection-induced liver fibrosis or cirrhosis, viral infection-induced fibrosis or cirrhosis, HBV-infection induced liver fibrosis or cirrhosis, HCV-infection induced liver fibrosis or cirrhosis, HIV-infection induced liver fibrosis or cirrhosis, dual HCV and HIV-infection induced liver fibrosis or cirrhosis, radiation- or
25 chemotherapy-induced fibrosis or cirrhosis, biliary tract fibrosis, liver fibrosis or cirrhosis due to any chronic cholestatic disease, gut fibrosis of any etiology, Crohn's disease-induced fibrosis, ulcerative colitis-induced fibrosis, intestine (e.g. small intestine) fibrosis, colon fibrosis, stomach fibrosis, lung fibrosis, lung fibrosis consecutive to chronic inflammatory airway diseases, such as COPD, asthma, emphysema, smoker's lung, tuberculosis,
30 pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF).